10X Stock Based Compensation from 2010 to 2024
| TXG Stock | USD 15.30 0.99 6.92% |
Stock Based Compensation | First Reported 2018-03-31 | Previous Quarter 38.5 M | Current Value 33.6 M | Quarterly Volatility 16 M |
Check 10X Genomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among 10X Genomics' main balance sheet or income statement drivers, such as Tax Provision of 3.7 M, Net Interest Income of 17.7 M or Interest Income of 17.8 M, as well as many indicators such as Price To Sales Ratio of 14.35, Dividend Yield of 0.0 or PTB Ratio of 5.94. 10X financial statements analysis is a perfect complement when working with 10X Genomics Valuation or Volatility modules.
10X | Stock Based Compensation |
Latest 10X Genomics' Stock Based Compensation Growth Pattern
Below is the plot of the Stock Based Compensation of 10X Genomics over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. 10X Genomics' Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in 10X Genomics' overall financial position and show how it may be relating to other accounts over time.
| Stock Based Compensation | 10 Years Trend |
|
Stock Based Compensation |
| Timeline |
10X Stock Based Compensation Regression Statistics
| Arithmetic Mean | 43,530,833 | |
| Geometric Mean | 8,046,380 | |
| Coefficient Of Variation | 151.24 | |
| Mean Deviation | 54,137,244 | |
| Median | 1,661,000 | |
| Standard Deviation | 65,837,998 | |
| Sample Variance | 4334.6T | |
| Range | 173.6M | |
| R-Value | 0.83 | |
| Mean Square Error | 1444.3T | |
| R-Squared | 0.69 | |
| Significance | 0.0001 | |
| Slope | 12,234,159 | |
| Total Sum of Squares | 60685T |
10X Stock Based Compensation History
Other Fundumenentals of 10X Genomics
10X Genomics Stock Based Compensation component correlations
Click cells to compare fundamentals
About 10X Genomics Financial Statements
10X Genomics stakeholders use historical fundamental indicators, such as 10X Genomics' Stock Based Compensation, to determine how well the company is positioned to perform in the future. Although 10X Genomics investors may analyze each financial statement separately, they are all interrelated. For example, changes in 10X Genomics' assets and liabilities are reflected in the revenues and expenses on 10X Genomics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in 10X Genomics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Stock Based Compensation | 166.9 M | 175.3 M | |
| Stock Based Compensation To Revenue | 0.27 | 0.28 |
Currently Active Assets on Macroaxis
When determining whether 10X Genomics is a strong investment it is important to analyze 10X Genomics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact 10X Genomics' future performance. For an informed investment choice regarding 10X Stock, refer to the following important reports:Check out the analysis of 10X Genomics Correlation against competitors. For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 10X Genomics. If investors know 10X will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 10X Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 5.261 | Quarterly Revenue Growth (0.01) | Return On Assets (0.11) | Return On Equity (0.25) |
The market value of 10X Genomics is measured differently than its book value, which is the value of 10X that is recorded on the company's balance sheet. Investors also form their own opinion of 10X Genomics' value that differs from its market value or its book value, called intrinsic value, which is 10X Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 10X Genomics' market value can be influenced by many factors that don't directly affect 10X Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 10X Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if 10X Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 10X Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.